Name | (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum(II) |
Synonyms | DACHPM Miripla SM-11355 SM 11355 SMP-11355 Miriplatin DACHPt(II)(Myr)2 [(1R,2R)-1,2-Cyclohexanediamine]bis(myristato)platinum (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis... (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum (SP-4-2)-[(1R,2R)-1,2-Cyclohexanediamine-kappaN,kappaN'])bis(myristato-kappaO)platinum(II) |
CAS | 141977-79-9 |
Molecular Formula | C34H66N2O4Pt |
Molar Mass | 762 |
Solubility | 10 mM in DMSO |
Storage Condition | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
In vitro study | Miriplatin (SM-11355) suspended in LPD (miriplatin/LPD, 100 μg/mL) inhibits the growth of AH109A cells, forms platinum-DNA adducts, and induces apoptosis. |
In vivo study | Miriplatin (SM-11355) (0.02-0.4 mg/20 μL) in lipiodol reduces tumor growth rates in a dose dependent manner in rats bearing AH109A tumor cells. Miriplatin/LPD (400 μg/head) significantly reduces the growth of tumor in rats bearing AH109A cells. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.309 ml | 6.545 ml | 13.089 ml |
5 mM | 0.262 ml | 1.309 ml | 2.618 ml |
10 mM | 0.131 ml | 0.654 ml | 1.309 ml |
5 mM | 0.026 ml | 0.131 ml | 0.262 ml |